Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramelteon for BZD dose reduction in chronic insomnia
NCT03461042Phase 4Completed
- Sponsor
- Translational Research Center for Medical Innovation
- Start
- Feb 2018
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Insomnia comparing Ramelteon Group with Placebo Group (2 arms). Primary endpoints: Achievement ratio of the 50% dose reduction of (non-)BZD hypnotics at 12 weeks and Rate of subjects who achieved more than 50% dose reduction of (non-)BZD hypnotics at 12 weeks. Started Feb 2018; status: completed.
02
Drugs
ramelteon
03
Conditions
Insomnia
Beyond the preview
Go deeper on NCT03461042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03461042.